Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




LYN-Kinase Activation Associated with Imatinib Resistance in CML
Link ID 6998
Title LYN-Kinase Activation Associated with Imatinib Resistance in CML
Url http://www.medscape.com/viewarticle/576661?src=rss
Description The activation of the LYN kinase plays a role in some cases of imatinib resistance that are not caused by mutations in the amplification of the BCR-ABL gene in patients with chronic myelogenous leukemia. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Jun 26, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Medtronic Gets FDA Approval for Biliary Stents
  Medtronic Inc said on Thursday it received marketing clearance from the U.S. Food and Drug Administration for a biliary stent system to treat cancerous tumors in the bile duct. Reuters Health Information
Category:   Articles > Hematology-Oncology


2. EGFR Inhibitors in Advanced Stage NSCLC: Latest Principles and Practice
  Is there a new role for EGFR inhibitors in the treatment of lung cancer? In this expert column, Dr. Neil and Dr. Heist review the latest data. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


3. Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine T
  Understanding the relationship between tumor response and relapse risk could help determine additional treatment options for patients who have received neoadjuvant endocrine treatment.
Journal of the National Cancer Institute
Category:   Articles > Hematology-Oncology


4. New Therapeutic Options in CML and What They Mean for Patients: An Expert Interview With Dr. Jorge C
  In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML.
Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


5. FDA Safety Changes: Campath and Trileptal
  The FDA has approved revisions to the safety labeling for alemtuzumab intravenous injection (Campath) and oxcarbazepine tablets/oral suspension (Trileptal). Medscape Medical News
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS